DataString Consulting Company Logo
DataString Consulting Company Logo
Vadadustat Market
Home»Top Market Reports»Vadadustat Market

Vadadustat Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802563, Published - June 2025

Segmented in Formulation Type (Oral, Injectable), Patient Demographics (Pediatric, Adult, Geriatric), Application, Distribution Channel and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Vadadustat Market Outlook

The market, for Vadadustat was estimated at $766.3 million in 2024; and it is anticipated to increase to $1.1 billion by 2030 with projections indicating a growth to around $1.6 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 7.0% over the forecast period. The steady growth in Vadadustat market underscores the drugs ongoing relevance in the healthcare industry. The market expansion is fuelled by key driving factors such as increasing prevalence of chronic kidney disease , enhanced focus on research and development, advancements in novel anemia therapies, and the persistent need for safer and more effective treatment options. Simultaneously, Vadadustats potential in addressing unmet medical needs and improving patient outcomes continue to support its prominence.


An overview of Vadadustat reveals it as an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to stimulate erythropoiesis. The drug is steadily gaining traction as an alternative to Erythropoiesis Stimulating Agents for treating anemia associated with CKD. Significantly, the trend toward personalized medicine and the growing awareness pertaining to the benefits of vadadustat have been instrumental in driving its demand.


Market Size Forecast & Key Insights

2019
$766M2024
2029
$1.5B2034

Absolute Growth Opportunity = $741M

The Vadadustat market is projected to grow from $766.3 million in 2024 to $1.51 billion in 2034. This represents a CAGR of 7.0%, reflecting rising demand across Chronic Kidney Disease Treatment, Therapeutic Areas of Non-Dialysis Dependent Chronic Kidney Disease and Dialysis Anemia Management.

The Vadadustat market is set to add $741 million between 2024 and 2034, with manufacturer targeting Adult & Geriatric Patient Demographics projected to gain a larger market share.

With The rising prevalence of anemia, and Advances in renal disease therapeutics, Vadadustat market to expand 97% between 2024 and 2034.

Opportunities in the Vadadustat Market

Strategic Collaborations for Drug Expansion

Strategic collaborations with hospitals, health clinics, and even other pharmaceutical companies can provide a new growth avenue for Vadadustat. These alliances will not only provide resource sharing but also an extended network for distribution and marketing of the drug.

Scaling Potential with Technological Innovation and Targeting Emerging Economies

The ever-progressing technological landscape presents a significant growth for Vadadustat. With advancements such as AI and ML, the optimization of Vadadustats drug discovery and delivery process can be achieved. This not only speeds up research and development but also ensures precision and efficiency, leading to improved patient outcomes. Incorporating these novel technologies may greatly boost the market position of Vadadustat.

Emerging economies present a lucrative prospect due to their growing healthcare infrastructure and increasing rate of chronic diseases, especially related to kidney ailments. Countries like India, Brazil, and South Africa are unventured frontiers where Vadadustat can fill the gap with its highly effective treatment solutions. The expansion to these markets can greatly benefit the overall growth and global footprint of Vadadustat.

Growth Opportunities in North America and Asia-Pacific

Asia Pacific Outlook

In the Asia-Pacific region, there is a burgeoning demand for Vadadustat, especially from rapidly developing countries like China and India. Population growth and an increasing prevalence of chronic health conditions fuel this demand. Local generic manufacturers and international pharmaceutical giants are competing fiercely, which has resulted in an escalating need for strategic alliances and partnerships. The main drivers in this region are streamlined regulatory oversight, market-friendly policies, and the evolving healthcare infrastructure, all of which are advancing Vadadustats market penetration.

North America Outlook

North America, likely the most prominent region in the Vadadustat market, has extensively leveraged the drugs benefits for chronic kidney disease patients. This factors into a steady demand, spurred on by research advancements and an aging population. The competitive landscape features heavyweights like Akebia Therapeutics and FibroGen, who have been involved in multiple clinical trials for the drug. However, continuous innovation and evidence-driven strategies are key drivers that are furthering Vadadustats expansive market footprint in the region.

North America Outlook

North America, likely the most prominent region in the Vadadustat market, has extensively leveraged the drugs benefits for chronic kidney disease patients. This factors into a steady demand, spurred on by research advancements and an aging population. The competitive landscape features heavyweights like Akebia Therapeutics and FibroGen, who have been involved in multiple clinical trials for the drug. However, continuous innovation and evidence-driven strategies are key drivers that are furthering Vadadustats expansive market footprint in the region.

Asia-Pacific Outlook

In the Asia-Pacific region, there is a burgeoning demand for Vadadustat, especially from rapidly developing countries like China and India. Population growth and an increasing prevalence of chronic health conditions fuel this demand. Local generic manufacturers and international pharmaceutical giants are competing fiercely, which has resulted in an escalating need for strategic alliances and partnerships. The main drivers in this region are streamlined regulatory oversight, market-friendly policies, and the evolving healthcare infrastructure, all of which are advancing Vadadustats market penetration.

Growth Opportunities in North America and Asia-Pacific

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Japan, Germany, France, UK are expected to grow at 4.5% to 6.7% CAGR

2

Emerging Markets : India, Brazil, South Africa are expected to grow at 8.0% to 9.7% CAGR

Market Analysis Chart

Expanding research in the field of anemia therapies has led to the development of Vadadustat, a key player in this realm. Rising health awareness and the global increase in anemia patients, particularly in populations suffering from chronic kidney disease, have propelled the growth and popularity of Vadadustat. Its favorable clinical profile, compared to other treatments, positions it as a viable treatment option and hence is expected to provide a significant driving force for its market growth.

Recent Developments and Technological Advancement

December 2024

AstraZeneca, a leading pharmaceutical company, announced FDA approval for Vadadustat used in the treatment of anemia associated with Chronic Kidney Disease in non-dialysis dependent patients

October 2024

FibroGen secured patent protection for their novel formulation of Vadadustat, further strengthening their innovative position in the industry

July 2024

Clinical trials of Vadadustat led by Mitsubishi Tanabe Pharma demonstrated remarkable efficacy in increasing haemoglobin levels in dialysis-dependent CKD patients.

Vadadustat has been making innovative strides in the pharmaceutical world, particularly within the chronic kidney disease treatment market. Its recent market developments suggest an optimistic glimpse at the potential avenues this drug can unlock.

Impact of Industry Transitions on the Vadadustat Market

As a core segment of the Pharmaceutical industry, the Vadadustat market develops in line with broader industry shifts. Over recent years, transitions such as From EPO based Anemia Treatments to HIFPHI Therapies and Advancements in Personalized Medicine Personalized Medicine Revolution have redefined priorities across the Pharmaceutical sector, influencing how the Vadadustat market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

From EPO based Anemia Treatments to HIFPHI Therapies:

Over recent years, the industry has been witnessing an important transition from Erythropoiesisstimulating agent based treatments to Hypoxia Inducible FactorProlyl Hydroxylase Inhibitor therapies such as Vadadustat. This novel approach in managing anemia related to chronic kidney disease provides potential benefits over traditional treatments such as reduced cardiovascular risks and need for dialysis. The advent of Vadadustat is a prime example of the increasing preference for this cuttingedge, transformative therapy.

2

Advancements in Personalized Medicine Personalized Medicine Revolution:

Modern medicine has dramatically advanced towards adopting personalized treatment strategies that take into account individual variability in genes and environment. Vadadustat is an illustrious example of this evolution, considering its novel mechanism of action that mimics the bodys natural response to hypoxia.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Vadadustat market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: The Rising Prevalence of Anemia

An increase in the global prevalence of anemia, especially among the aging population, is also driving the market demand for Vadadustat. This novel medication, known for its proven effectiveness in treating anemia associated with Chronic Kidney Disease , is also set to witness stellar growth paths. As the number of anemia patients continues to surge, this would also increase the demand for Vadadustat, a promising solution for anemia management.
Emergence of breakthroughs and advancements in therapeutics of kidney diseases is also another majorthatsaccelerating Vadadustats market prospects. In the quest for effective CKD treatments, Vadadustat, as a novel hypoxia-inducible factor prolyl hydroxylase inhibitor, gains prime focus. The medication showcases an optimal way to stimulate natural erythropoiesis minimizing the risk of the drastic side effects linked with the current treatment options. Intensified research and development in the CKD therapeutics space leading to such novel medicines further underpins the growing demand for Vadadustat.

Restraint: Regulatory Hurdles

The market for Vadadustat faces significant challenges in the form of regulatory roadblocks. The molecule has yet to gain approval from regulatory bodies in certain regions around the globe, including the highly coveted U. S. Food and Drug Administration approval. This inevitably restricts the commercial reach of Vadadustat, limiting its potential market growth and revenue generation. Although efforts are continually being made to gain these crucial approvals, the complex and lengthy process can cause significant delays, detrimentally affecting the market dynamics for this innovative therapeutic agent.

Challenge: Competition from Established Treatments

The second major negatively impacting market growth for Vadadustat is the competition it faces from already established treatments. In the therapeutic area of anemia due to chronic kidney disease, where Vadadustat aims to make a significant impact, medicines like Aranesp and Epogen have a firm market presence.

Supply Chain Landscape

Raw Material Acquisition

Fujifilm Diosynth Biotechnologies

Cambridge Major Laboratories

Production

Akebia Therapeutics

Mitsubishi Tanabe Pharma

Distribution & Logistics
Teva Pharmaceutical Industries / Sandoz International
End-Users
Pharmaceutical R&D
Raw Material Acquisition

Fujifilm Diosynth Biotechnologies

Cambridge Major Laboratories

Production

Akebia Therapeutics

Mitsubishi Tanabe Pharma

Distribution & Logistics

Teva Pharmaceutical Industries

Sandoz International

End-Users

Pharmaceutical R&D

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Treatment of Anemia
Pharmaceuticals
Akebia Therapeutics
The primary approach of Akebia is developing Vadadustat as an alternative to current erythropoiesis-stimulating agents (ESAs), specifically for CKD patients on dialysis and not on dialysis
Renal Care
Pharmaceuticals
Mitsubishi Tanabe Pharma
Their strategy involves adopting Vadadustat for treating anemia associated with chronic kidney disease (CKD) due to its potential higher efficacy and less adverse effects
Cardiovascular Care
Pharmaceuticals
FibroGen
FibroGen aims to use Vadadustat to address the high unmet clinical need associated with cardiac surgery risk in anemic patients undergoing cardiopulmonary bypass surgery

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Vadadustat market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Vadadustat in Therapeutic Areas of Non-Dialysis Dependent Chronic Kidney Disease, Dialysis Anemia Management and Chronic Kidney Disease Treatment

Therapeutic Areas of Non-Dialysis Dependent Chronic Kidney Disease

Vadadustat has shown noteworthy efficacy in the treatment of non-dialysis dependent chronic kidney disease, filling a significant gap in this therapeutic region.

Dialysis Anemia Management

Another significant application of Vadadustat is in managing anemia in patients undergoing dialysis. It serves as an alternative to erythropoiesis-stimulating agents , offering the advantage of oral administration and fewer side effects. Vadadustat is primarily beneficial in enhancing the bodys natural response to low oxygen levels and promoting red blood cell production. Top players in this market include FibroGen Inc. and AstraZeneca, commended for their exceptional contribution to dialysis-associated anemia care.

Chronic Kidney Disease Treatment

Vadadustat is widely used in the treatment of Chronic Kidney Disease.This is an anemia-associated prescribed medication, primarily focusing on boosting the production of red blood cells. Vadadustat works by inhibiting hypoxia-inducible factor-prolyl hydroxylase, stimulating natural erythropoiesis - the process that produces red blood cells in the human body. Notable players in this market include major pharmaceutical companies like Akebia Therapeutics and Otsuka Pharmaceuticals, recognized for their robust pipeline and consistent innovation in CKD treatment.

Vadadustat vs. Substitutes:
Performance and Positioning Analysis

Vadadustat, a novel medication aimed at treating anemia due to chronic kidney disease, holds a unique growth potential, distinctly outperforming its alternatives in terms of efficacy, safety, and patient adaptability

Vadadustat
  • Roxadustat /
  • Daprodustat
    Effective in treating anemia associated with chronic kidney disease, Potential for improving cardiovascular health
    Limited use due to not yet being approved in several countries, Potential side effects including hyperk
    Alternative treatments have strong clinical success rates, established market presence
    However, they often come with severe side effects, higher costs

Vadadustat vs. Substitutes:
Performance and Positioning Analysis

Vadadustat

  • Effective in treating anemia associated with chronic kidney disease, Potential for improving cardiovascular health
  • Limited use due to not yet being approved in several countries, Potential side effects including hyperk

Roxadustat / Daprodustat

  • Alternative treatments have strong clinical success rates, established market presence
  • However, they often come with severe side effects, higher costs

Vadadustat, a novel medication aimed at treating anemia due to chronic kidney disease, holds a unique growth potential, distinctly outperforming its alternatives in terms of efficacy, safety, and patient adaptability

Loading...

Research Methodology

This market research methodology defines the Vadadustat market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Vadadustat across Chronic Kidney Disease and Cancer Anemia Treatment Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Akebia Therapeutics, FibroGen, and GlaxoSmithKline by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Acquisition, Production, and Distribution & Logistics. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Vadadustat segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Acquisition (Fujifilm Diosynth Biotechnologies, Cambridge Major Laboratories), Production (Akebia Therapeutics, Mitsubishi Tanabe Pharma), and Distribution & Logistics. Our parallel substitute analysis examines Roxadustat and Daprodustat, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Akebia Therapeutics, FibroGen, and GlaxoSmithKline, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Vadadustat market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Vadadustat Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 819 million
Revenue Forecast in 2034USD 1.51 billion
Growth RateCAGR of 7.0% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024766 million
Growth OpportunityUSD 741 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024766 million USD
Market Size 2027938 million USD
Market Size 20291.07 billion USD
Market Size 20301.15 billion USD
Market Size 20341.51 billion USD
Market Size 20351.61 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredFormulation Type, Patient Demographics, Application, Distribution Channel
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledAkebia Therapeutics, FibroGen, GlaxoSmithKline, AstraZeneca, Bayer AG, Johnson & Johnson, Novartis International AG, Pfizer Inc, Roche Holding AG, Eli Lilly and Company, Amgen Inc and Daiichi Sankyo Company Limited.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Vadadustat Market Size, Opportunities & Strategic Insights, by Formulation Type

4.1Oral
4.2Injectable
Chapter 5

Vadadustat Market Size, Opportunities & Strategic Insights, by Patient Demographics

5.1Pediatric
5.2Adult
5.3Geriatric
Chapter 6

Vadadustat Market Size, Opportunities & Strategic Insights, by Application

6.1Chronic Kidney Disease
6.2Cancer Anemia Treatment
Chapter 7

Vadadustat Market Size, Opportunities & Strategic Insights, by Distribution Channel

7.1Hospital Pharmacies
7.2Retail Pharmacies
7.3Online Pharmacies
Chapter 8

Vadadustat Market, by Region

8.1North America Vadadustat Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Vadadustat Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Vadadustat Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Vadadustat Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Vadadustat Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Vadadustat Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Akebia Therapeutics
9.2.2FibroGen
9.2.3GlaxoSmithKline
9.2.4AstraZeneca
9.2.5Bayer AG
9.2.6Johnson & Johnson
9.2.7Novartis International AG
9.2.8Pfizer Inc
9.2.9Roche Holding AG
9.2.10Eli Lilly and Company
9.2.11Amgen Inc
9.2.12Daiichi Sankyo Company Limited.